MetaCap

Fulcrum Therapeutics (FULC) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 38.6% versus a loss of 67.3%. Over five years, FULC leads with a -75.5% price change compared with -86.1% for RLMD. Fulcrum Therapeutics is the larger company by market cap ($281.8 million vs $279.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FULC-67.32%RLMD-38.64%
+92%+6%-80%
Nov 21, 20251 yearNov 20, 2026
FULC-78.47%RLMD-87.15%
+91%-9%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FULC versus RLMD key metrics
MetricFULCRLMD
Share price$3.69$2.62
Market cap$281.85M$279.54M
1-day change-0.54%-15.76%
YTD return-67.37%-45.76%
1-year return-67.32%-38.64%
5-year return-75.50%-86.09%
EPS (TTM)$-1.04$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-74.88M$-57.39M
52-week high$15.74$8.00
52-week low$2.83$2.60
Distance from 52-week high-76.56%-67.25%
Analyst consensusholdstrong_buy
Avg. price target upside-0.54%+310.31%
Average volume1.37M1.45M
Shares outstanding76.38M106.69M
Employees5517
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLMD has outperformed FULC by 28.7 percentage points over the past year.

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

FULC vs RLMD FAQ

Which is bigger, Fulcrum Therapeutics or Relmada Therapeutics?

Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.85M compared with $279.54M for Relmada Therapeutics (RLMD).

Which stock has performed better over the past year, FULC or RLMD?

RLMD returned -38.64% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.

Are Fulcrum Therapeutics and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons